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Background: Costs of tobacco-related disease can be useful evidence to support tobacco control. In Hong
Kong we now have locally derived data on the risks of smoking, including passive smoking.
Aim: To estimate the health-related costs of tobacco from both active and passive smoking.
Methods: Using local data, we estimated active and passive smoking-attributable mortality, hospital
admissions, outpatient, emergency and general practitioner visits for adults and children, use of nursing
homes and domestic help, time lost from work due to illness and premature mortality in the productive
years. Morbidity risk data were used where possible but otherwise estimates based on mortality risks were
used. Utilisation was valued at unit costs or from survey data. Work time lost was valued at the median
wage and an additional costing included a value of US$1.3 million for a life lost.
Results: In the Hong Kong population of 6.5 million in 1998, the annual value of direct medical costs, long
term care and productivity loss was US$532 million for active smoking and US$156 million for passive
smoking; passive smoking accounted for 23% of the total costs. Adding the value of attributable lives lost
brought the annual cost to US$9.4 billion.
Conclusion: The health costs of tobacco use are high and represent a net loss to society. Passive smoking
increases these costs by at least a quarter. This quantification of the costs of tobacco provides strong
motivation for legislative action on smoke-free areas in the Asia Pacific Region and elsewhere.
T
here is steadily mounting evidence of the harm caused to
health by active and passive tobacco smoking1 2 but
policymakers can be reluctant to implement stricter
legislation to protect non-smokers and restrict promotion of
tobacco products. One way of enhancing appreciation of the
magnitude of the problem is to transform the data on health
effects of tobacco-induced disease into monetary values. This
has been done to good effect in the United States where costs
attributable to smoking were estimated to be over US$157
billion3 with attributable direct health costs taking up 6–9%
of the total national health care budget.4 5 Other countries
have followed suit and calculated their own financial burdens
resulting from tobacco use.6–9 However, it is difficult to
extrapolate from developed to developing countries where
the tobacco epidemic is usually at an earlier stage.
Furthermore, none of the costings in developing countries
and few of those in developed countries have included any
costs for passive smoking. In Hong Kong, a special admin-
istrative region of China, the prevalence of regular smoking
among men in 2000 was 22%,10 much lower than that
of mainland China where over 53% of males smoked in
1998.11 The current peak in the prevalence of cigarette
smoking in China occurred about 40 years later than in the
United States but post dates that in Hong Kong by about
20 years. Although the effect of smoking is probably not
yet fully expressed in terms of health impact in either
Hong Kong or mainland China, the future burden of health
costs in the mainland can be predicted from Hong Kong’s
experience.
A previous attempt to cost the health effects of smoking in
Hong Kong12 used overseas risk data because at that time
there were no locally generated data. Since then local data
on the risks of active and passive smoking have been
published13–20 which allow us to estimate the monetary value
of tobacco-related disease. The main objectives of this
costing were to raise awareness among local and regional
decision-makers of the true costs of tobacco to both smokers
and non-smokers and to promote tobacco control legislation.
This paper describes the costing and its findings.
METHODS
We limited the costing to health-related impacts and so the
values reported in this study are extremely conservative. We
made 1998 the base year because we had detailed data on
81% of the deaths which occurred in that year through the
University of Hong Kong Lifestyle and Mortality Study
(LIMOR). From this study the risks of mortality from active
smoking for those aged 35 years and over13 and for passive
smoking for those aged 60 years and over,14 have been
published.
Mortality caused by active smoking
We re-analysed the LIMOR dataset to obtain mortality from
active smoking by age group (35 to 64, 65 and over), sex and
cause of death (table 1). Using these risk estimates we
calculated the fraction of deaths which could be attributed to
active smoking. Since we knew the proportion of decedents
who smoked, we could estimate the attributable fraction of
those exposed21 as the smoking-attributable fraction (SAF)
for the smokers using the formula: SAF = [OR 2 1]/OR,
where OR is the odds ratio for disease-specific mortality
caused by smoking.
Applying the SAFs to all deaths among smokers, also by
disease, age and sex, we estimated the attributable number of
lives lost at any age and under 65 years adjusted for the
labour force participation rate. Using the difference between
age at death and 65 years, we calculated average productive
years lost, discounting at 3% per annum, and monetised the
losses by valuing a working year at the median wage in 1998.
Abbreviations: COPD, chronic obstructive pulmonary disease; IHD,
ischaemic heart disease; LIMOR, University of Hong Kong Lifestyle and
Mortality Study; OR, odds ratio; PAF, population attributable fraction;
SAF, smoking-attributable fraction
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We valued an attributable death using the value of 1.4
million euros (J), a middle estimate worldwide which was
used in a European valuation of air pollution related deaths.22
With an exchange rate of J1 to HK$7.2, this was equivalent
to HK$10 million or US$1.3 million. We present the results
both with and without the monetary value for a life lost.
We used the groupings of cause of death reported in two
studies from China.13 23 However, the ‘‘other medical’’ group
was large and diverse so we limited it to conditions
recognised as tobacco-related by other studies (table 1). We
included liver cancer because of its high incidence in China
and Hong Kong and its strong association with smoking. We
did not include pregnancy-related conditions because smok-
ing prevalence among women in Hong Kong is low.
Mortality caused by passive smoking
This was calculated in the same way and using the same
dataset as for active smoking with data on exposure to
secondhand smoke in never-smokers over 60 years old,
exposed at home.14 We included only the four causes of death
which have been associated with passive smoking—that is,
lung cancer, chronic obstructive pulmonary disease (COPD),
ischaemic heart disease (IHD), and stroke. The LIMOR
dataset did not provide information about workplace
exposures to secondhand smoke but there is increasing
evidence that exposure at work is just as harmful as exposure
at home.24–26 We therefore extrapolated the estimated risks of
home exposure to those exposed at work and further
extrapolated to never-smokers aged 35–59 years. We esti-
mated that 56% of males and 46% of females over 35 years
were exposed to secondhand smoke.15 We used the popula-
tion attributable fraction (PAF)21 rather than the SAF
because we did not have direct data on the number of
deaths in all of those exposed to secondhand smoke. The
formula used was: PAF = (p [OR 2 1])/(1 + p [OR 2 1])
where p is the proportion of never-smokers exposed.
Costing of morbidity
For the costing of morbidity, we used directly derived risks of
morbidity as far as possible. For example, for the impact of
active smoking and of passive smoking at work on general
practitioner (GP) visits we were able to use local published
data15 20 to calculate PAFs of health care utilisation and their
costs. We could also do this for the impact of passive smoking
on children. For the costs due to passive smoking by children
less than 1 year old we used results from a local birth
cohort.18 From another local study on 8–12 year old children19
we extrapolated the excess doctor visits caused by passive
smoking and their costs to children between 1–15 years old.
These estimates omit some of the early life impacts caused by
passive smoking or smoking by the mother, for example, on
sudden infant death syndrome, low birth weight and other
birth complications, therefore these costs are underestimated.
Recent costings in the United States used data on risks of
hospital utilisation by smoking status but we had no data on
smoking status of inpatients. Therefore, for costs of serious
illness resulting in hospital admission, we used disease, age
and sex specific PAFs which were derived using the
corresponding mortality risks. We applied these PAFs to data
on admissions which were obtained from the Hong Kong
Hospital Authority clinical medical system. This information
system includes all discharges and deaths in public hospitals
in Hong Kong and covers around 94% of the hospital bed-
days used in Hong Kong.27 For consultations in public
outpatient clinics and accident and emergency departments,
we could not obtain disease, age and sex-specific utilisation
or cost data. Therefore, for active smoking, we used a PAF
based on the smoking-related risk of mortality from any
cause for all ages and both sexes together but we omitted
these costs for passive smoking. The Hospital Authority
supplied the unit average cost of bed-days in acute and long-
stay hospitals and outpatient visits. For private hospitals, we
obtained the number of admissions from routine data28 and
used charge data from BUPA (Asia) Limited,29 but omitted
any costs of private hospital utilisation for passive smoking-
related conditions.
Other data sources
For population data on the prevalence of active and passive
smoking, health care utilisation and the average cost of a GP
visit, we used the University of Hong Kong-Harvard
Household Survey from which some of the data have been
published.15 For time lost from work, we used the University
of Hong Kong Police Health Survey from which we have
already published findings on the association between
passive smoking, respiratory symptoms, health care utilisa-
tion and time off work.16 17 We calculated from this database
the risk of taking time off work for a smoker compared with a
never-smoker and used this together with an estimate of
smoking prevalence among workers15 and annual working
days lost30 to estimate days lost attributable to smoking.
These were valued at the median wage in 199831 and were
attributed to the public or private sector based on the
proportion of employees in these sectors.32 33
Table 1 Causes of death and odds ratios (OR) used in the calculation of attributable fractions to estimate health-related costs
of active and passive smoking
Cause of death (ICD 9 code)
OR (95% CI) for mortality as used in the costing
Active smoking Passive smoking
Age 35 to 64 Age 65 and over All ages
Lung cancer (162) 3.8 (3.1 to 4.7) 4.6 (4.1 to 5.2) 1.4 (1.0 to 1.9)
Oesophageal cancer (150) 8.1 (4.6 to 14.3) 2.5 (1.8–3.7)
Stomach cancer (151) 1.7 (1.2 to 2.4) 1.2 (0.9 to 1.5)
Liver cancer (155) 1.5 (1.2 to 1.8) 1.4 (1.1 to 1.6)
Mouth, pharynx, larynx, pancreas, bladder cancer (140–149, 157, 161, 188) 1.7 (1.3 to 2.2) 1.8 (1.5 to 2.2)
COPD/pulmonary heart disease (416–417, 490–492, 496) 5.0 (3.1 to 8.0) 5.8 (5.0 to 6.7) 2.0 (1.3 to 3.1)
Other respiratory (11, 12, 18, 460–466, 470–478, 480–483, 485–487,
493–495, 500–508, 510–516, 518–519)
2.0 (1.5 to 2.6) 1.5 (1.4 to 1.7)
Stroke (430–438) 1.8 (1.4 to 2.3) 1.2 (1.0 to 1.3) 1.5 (1.2 to 1.9)
Ischaemic heart disease (410–414) 1.7 (1.3 to 2.2) 1.3 (1.2 to 1.4) 1.4 (1.0 to 1.8)
Other vascular (390–398, 401–405, 415, 420–429, 440–444, 446–448,
451–459)
1.9 (1.4 to 2.6) 1.3 (1.2 to 1.5)
Other medical: peptic, gastric, duodenal, gastrojejunal ulcer, regional enteritis,
idiopathic proctocolitis (531–534, 555–556)
2.7 (0.8 to 9.8) 1.4 (0.9 to 2.2)
CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICD 9, International classification of diseases, ninth revision; OR, odds ratio.
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We applied the PAF derived from the excess risk of
mortality from any cause for active smokers aged over 65
years to the number of people in nursing homes and
multiplied this by the annual unit cost of care.34 To estimate
the value of home care in the last year of life, we used
additional data from LIMOR on the length of time that the
decedent was unable to go outdoors alone in the year before
death. We multiplied the average time spent in this state by a
smoker by the number of deaths attributable to active
smoking and subtracted attributable inpatient days; we did
the same for passive smokers. These months of care were
valued by applying the proportions who would have domestic
help and the cost10 31 35 36; care provided by the family alone
was not monetised.
To calculate a range for the best estimate of costs, we used
the upper and lower bounds of the 95% confidence intervals
for the risk estimates and re-worked the costings. Whenever
we had alternative options for values, such as in the
estimation of the costs of private hospital inpatient episodes,
we used the lower option to give a conservative estimate. All
reported costs are in US dollars (US$1 = HK$7.8) and are
for one calendar year (1998).
RESULTS
We estimated that 5596 deaths among those 35 years and
over in Hong Kong in 1998 were attributable to active
smoking (table 2) and 1324 deaths were attributable to
passive smoking (table 3). Of the passive smoking attribu-
table deaths, 239 were from lung cancer, 303 from COPD, 309
from IHD and 473 from stroke. This amounts to 6920
tobacco-related deaths out of a total of 32 847 deaths in a
population of 6.5 million people in 1998.
The discounted value of productive years of life lost was
$174 million, $160 million for active smoking and $14 million
for passive smoking (tables 2 and 3). For adults, the
attributable cost of public hospital use was $230 million a
year, $169 million for active smoking and $61 million for
passive smoking (tables 2 and 3). This represents about 7% of
the Hospital Authority’s total expenditure on public hospitals
in 1998. The cost of visits to specialist outpatient clinics by
adults as a result of active smoking amounted to $19 million
(table 2) representing 5% of all visits to non-paediatric
specialist clinics. The value of the extra medical care due to
passive smoking exposure in children was $4 million a year
(table 3).
The cost of visits to public primary care outpatient clinics
which were attributable to active smoking was estimated as
$21 million which is 12% of the total cost for such clinics in
1998. The cost of attributable visits to accident and
emergency departments as a result of active smoking was
$8 million (table 2) or 5% of the cost of all visits. The
attributable cost of private GP consultations due to active
smoking was $12 million (table 2) and $32 million for passive
smoking (table 3).
The value of the attributable absences from work was $11
million for active smoking (table 2) and $45 million for
passive smoking (table 3). This does not include time taken
off work for doctor consultations or a period of suboptimal
productivity before doctor consultation and on return to
work.
The attributable cost of nursing home care in those over 65
years for disease due to active smoking was $117 million
while the cost of home-based care was $0.7 million (table 2).
For passive smoking, home-based care cost $0.3 million
(table 3) but we could not estimate the cost of nursing home
care for conditions caused by passive smoking.
Our conservative estimate of the annual health-related cost
of tobacco in Hong Kong in 1998 is $688 million with a range
of $469–$916 million. This includes $459 million for health
care costs ($341 million for medical care and $118 million for
long term care) and $230 million for productivity losses.
About 23% of the total costs and 28% of the medical care
costs were due to passive rather than active smoking. The
proportion of the morbidity costs which fell on the public
sector was 70% for active smoking and 50% for passive
smoking. In addition, there were 6920 (4430–9229) attribu-
table deaths of which 19% were attributable to passive
smoking. If we add the value of attributable lives lost but
deduct productivity loss due to premature death to avoid
double counting the value of a lost life, the annual cost would
be $9.4 billion.
Table 2 Summary of the annual costs (1998) for mortality and morbidity due to diseases
caused by active smoking
Component of cost
No. of attributable units,
best estimate (range) Unit cost (US$)
Value (US$ million),
best estimate (range)
Mortality
Total lives lost 5596 (4096–6978) 1.3 million 7193 (5265–8969)
Productive lives lost (,65 years) 1529 (1054–1942) – –
Productive life years lost (,65 years)
Undiscounted 10774 (7295–13837) Males: 18509 199 (134–255)
Discounted at 3% per year* 8669 (5889–11111) Females: 13882 160 (109–205)*
Morbidity
Public hospital days
Acute 270038 481 130 (89–166)
Long stay 152888 255 39 (29–49)
Private hospital episodes 6370 2505 16 (12–19)
Specialist outpatient clinics 256823 74 19 (16–22)
General outpatient clinics 714585 DH: 28, HA: 34 21 (19–22)
A&E (visits) 105661 74 8 (7–8)
Private GP (visits) 519962 23 12 (12–18)
Days off work (private sector) 170893 Males: 51 10 (0.5–15)
Days off work (public sector) 21610 Females: 38 1 (0.1–2)
Nursing home care 117 (106–128)
Home-based care 0.7 (0.5–0.8)
Annual costs for active smoking, excluding the value of life 532 (421–655)
*This is the value used in the main estimates of costs.
The numbers in the table are rounded and so may not sum to totals.
A&E, accident and emergency; DH, Department of Health; HA, Hospital Authority, GP, general practitioner.
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DISCUSSION
Our estimate of $688 million for the current annual monetary
value of the diseases caused by tobacco is larger than
previous estimates for Hong Kong. The Hospital Authority
previously estimated $90 million for hospital care for cancer,
heart and respiratory disease.37 Another costing based on
overseas risk estimates was $193 million annually at 1998
prices.12 Our costing is more comprehensive and uses locally
derived data for all risks and costs. It is also more
comprehensive than costings in other countries because we
were able to include estimates of costs for major health
problems associated with passive smoking, such as stroke
and COPD. Almost a quarter of the cost of tobacco-related
disease was due to the effects of passive smoking. Although
the risk from passive smoking exposures is likely to be lower
than that from active smoking, passive smoking is much
more prevalent and thus the aggregated costs are relatively
high.
The present study has limitations due to the non-
availability of some of the data required. First, we have used
attributable fractions derived from mortality risks to estimate
some of the morbidity costs. This allowed us to use local data
but requires us to make assumptions about comparability of
the risks. We do not have risk estimates for admission to
hospital for smokers relative to non-smokers but disease-
specific mortality risks should not overestimate attributable
admissions unless smokers use less hospital care than non-
smokers with the same disease. A cohort study from Korea38
demonstrates the relationship between the risks of mortality
and of hospital admission for current smokers in an East
Asian population. For lung cancer, the risks for mortality
(relative risk (RR) 4.0) and admission (RR 4.2) are almost the
same; for IHD, the risk of admission is higher (RR 1.5 and
2.0) and for stroke the risk of mortality is slightly higher (RR
1.8 and 1.4) but the risk does not vary much between the two
measures. Other studies of differences in utilisation between
smokers and non-smokers have identified a higher rate of
hospital utilisation by smokers.39–41 Much of this excess is
likely to be caused by a higher incidence of disease, which is
already reflected in our mortality-based disease specific
attributable risks.
Second, by using a population-based attributable fraction,
we make the assumption that the proportion exposed—for
example, among those admitted to hospital—is the same as
the proportion exposed in the general population. This
assumption is likely to lead to an underestimation of the
true cost of hospital-based care since smokers are usually
over-represented in a hospital population. Over-utilisation by
smokers is sometimes less apparent as we move down the
levels of care towards primary care services,42 but Miller et al43
found that smoking-attributable fractions for ambulatory
care were larger than those for hospital care in the United
States.
Third, for utilisation attributable to active smoking,
hospital inpatient costs were the largest item and we could
apportion these by age, sex and disease subgroups. However,
for some categories of care such as outpatient visits, we were
unable to separate out the effects of these variables and so
could have under- or overestimated these costs. Fourth, we
have used contemporary prevalence ratios for ever-smoking
when estimating the PAFs but current mortality and
morbidity result from smoking rates in the past. It would
require detailed data going back many years to estimate the
effect of this assumption. However, using the proportion of
ever-smokers rather than current smokers tends to smooth
out changes in smoking behaviour over time. Rising rates of
smoking among young people suggest that this costing may
be an underestimate of the burden of disease in the future.
Fifth, we had no specific risk data for the impact of passive
smoking on adults under 60 years old so we extrapolated the
risks for adults over 60 to those aged 35–59 years. The age of
35 has been identified as a significant cut-off point for active
smoking beyond which exposure is reflected in disease and
reduced life expectancy44 and table 1 shows that the risks of
mortality did not vary much with age beyond 35. We have
used the same cut-off for the impact of exposure due to
passive smoking. The number of attributable cases does
increase with age because the risks are applied to a greater
baseline rate of disease and this is incorporated by using age
and disease specific population rates of deaths and admis-
sions.
Finally, we have omitted some categories of health-related
costs. Our value of $1.3 million for a lost life attempts to put a
value on the suffering caused by the loss of a loved one, but
we have not included any value for pain and suffering due to
disease or the considerable input by families to the care of
their sick relatives, and we have only included four disease
groups in the costing of passive smoking in adults.
The estimate of days of work lost by passive smokers is
larger than that for active smokers, probably for two reasons.
Table 3 Summary of the annual costs (1998) for mortality and morbidity due to diseases
caused by passive smoking
Component of cost
No. of attributable units,
best estimate (range) Unit cost (US$)
Value (US$ million),
best estimate (range)
Mortality
Total lives lost 1324 (334–2251) 1.3 million 1702 (429–2893)
Productive lives lost (,65 years) 178 (38–310) – –
Productive life years lost (,65 years)
Undiscounted 1031 (211–1800) Males: 18500 18 (4–31)
Discounted at 3% per year* 815 (168–1423) Females: 13900 14 (3–24)*
Morbidity
Admissions and outpatient use in children 4 (–)
Public hospital days
Acute 88916 481 43 (13–70)
Long stay 69588 255 18 (6–29)
Private GP (visits) Approx 1500000 23 32 (3–60)
Days off work (private sector) 942409 Males: 51 41 (15–66)
Days off work (public sector) 102390 Females: 38 4 (2–7)
Home-based care 0.3 (0.1–0.5)
Annual costs for passive smoking, excluding the value of life 156 (48–261)
*This is the value used in the main estimates of costs.
The numbers in the table are rounded and so may not sum to totals.
The following could not be estimated: numbers and costs of episodes in a private hospital; specialist outpatient
clinic, general outpatient clinic and accident and emergency clinic visits; nursing home care.
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First, those who continue to smoke tend to be less susceptible
to its effects, the healthy smoker effect, or less health
conscious. In our analysis, the risk of taking time off work
was higher for passive (adjusted OR for males 1.80, 95%
confidence interval (CI) 1.41 to 2.30) than for active smokers
(OR 1.37, 95% CI 1.16 to 1.63). The same effect has been
shown for doctor consultations.39 42 45 46 Second, the preva-
lence of passive smoking is higher than that of active
smoking. Together, these data give a higher population
attributable fraction for passive than for active smoking.
In applying attributable risks to nursing home data, we
assumed that the attributable proportion of nursing home
use was similar to that for mortality. In the absence of
evidence to the contrary, we consider this a reasonable
assumption; the only alternative would be to drop this item
which would underestimate the costs.
Economic assessments sponsored by the tobacco industry
have, in the past, claimed net benefits from tobacco market-
ing and consumption.47 48 They often cite the tax revenue
from tobacco as a source of funds for the government and
claim that this tax revenue outweighs any excess health care
costs. While our costing has been unable to quantify some
categories of costs, our annual estimate of direct costs and
productivity loss alone is more than double the Hong Kong
SAR government’s annual revenue from tobacco tax.
Warner49 points out the weaknesses in previous economic
arguments put forward by both the tobacco industry and
tobacco control advocates. The issue most relevant to this
paper is that only those smoking-related costs which fall on
society are true social costs. For example, it could be argued
that the cost of premature mortality could be considered an
economic cost to the smoker’s family and not to society since
another worker would take over the role of the lost worker. If
we exclude all of those costs which we might assume to be
private costs, we have an estimate of $331 million for the
societal costs of smoking. Of our total costs, 64% fall on the
public sector but this proportion will be different in other
countries with different health and welfare systems.
The visits to primary care clinics attributable to active
smoking could be presented in units of working time. If we
assume that the average doctor sees 60 patients a day, five
days a week for 48 weeks of the year, then the attributable
visits represent the workload of 50 full-time doctors in the
public sector and 36 full-time GPs in the private sector. For
passive smoking, we have only estimated the extra workload
in the private sector which is the equivalent of 104 full-time
GPs. These ‘‘doctor-equivalents’’ are another useful means of
emphasising the real costs of disease burden on the
population.
Although some of our risk estimates for active smoking13
are lower than those in the West, they are similar to those
from Korea.38 They are therefore likely to be applicable to Asia
Pacific countries with a similar smoking history and will at
least reflect, for those countries like China with an even more
immature smoking epidemic, the likely future health care
burden. With few smoke-free laws in Hong Kong, many non-
smokers are probably exposed to a high level of background
smoking and this could be another reason for the lower
estimates of risk for active smoking.
The costs of passive smoking in any country will depend to
a great extent on its prevalence. In our estimates we used an
exposure prevalence of about 50% but biochemical measures
often show self-reported exposure to be an underestimate.50
If the prevalence of passive smoking was higher than we have
estimated, the associated costs would be higher too. If those
in other countries wish to use our example to estimate their
own passive smoking costs, they could upwardly adjust their
costs of active smoking by multiplying by 1.3 to include costs
due to passive smoking. They should, however, note that the
prevalence of active smoking in Hong Kong is lower than in
most Asia Pacific countries; it is therefore quite likely that
other population’s passive smoking burden is even higher
than in Hong Kong, unless there is effective protection for
non-smokers in public places, workplaces and their own
homes.
These findings will give a strong boost to the Hong Kong
government’s aim to promote tobacco control and the
urgently needed evidence on which to base legislation.
Stronger arguments citing health costs can be made against
the catering industry’s proposals for extended ‘‘grace
periods’’ before implementation of smoke-free legislation
covering all restaurants and bars. Each day of delay in
implementing the legislation in Hong Kong can now be
translated into an additional monetary burden to the
community.
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